Literature DB >> 1079469

Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole.

W T Hughes, S Feldman, S K Sanyal.   

Abstract

Pneumocystis carinii pneumonitis (PCP) is fatal in 90 to 100% of the cases if no treatment is given. Trimethoprim-sulfamethoxazole (TMP-SMX) was used at one of two dosage levels in the treatment of 20 children with PCP and cancer. Of 14 patients treated with 20 mg TMP--100 mg SMX/kgd, 12 recovered and 2 died. Treatment of the fatal cases and one of the patients who recovered was supplemented with pentamidine. When six patients were treated with 4 to 7 mg TMP--20 to 35 mg SMX/kgd, four recovered and two died. Both fatal cases and one of the patients who recovered were also treated with pentamidine. There was no significant adverse effects from TMP-SMX.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1079469      PMCID: PMC1956451     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  11 in total

1.  Pneumocystis carinii pneumonitis in children with malignancies.

Authors:  W T Hughes; R A Price; H K Kim; T P Coburn; D Grigsby; S Feldman
Journal:  J Pediatr       Date:  1973-03       Impact factor: 4.406

Review 2.  Descriptive epidemiology of interstitial pneumocystic pneumonia. An analysis of 107 cases from the United States, 1955-1967.

Authors:  R A Le Clair
Journal:  Am Rev Respir Dis       Date:  1969-04

3.  Clinical experience with adverse reactions to trimethoprim-sulfamethoxazole.

Authors:  J M Frisch
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

4.  Recurrent pneumocystis carinii pneumonia following apparent recovery.

Authors:  W T Hughes; W W Johnson
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

5.  Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia.

Authors:  K A Western; D R Perera; M G Schultz
Journal:  Ann Intern Med       Date:  1970-11       Impact factor: 25.391

6.  Pneumocystis carinii pneumonia treated with pyrimethamine and sulfadiazine.

Authors:  H B Kirby; B Kenamore; J C Guckian
Journal:  Ann Intern Med       Date:  1971-10       Impact factor: 25.391

7.  Pneumocystis carinii infection in the immunosuppressed host.

Authors:  J Ruskin; J S Remington
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

8.  Latent Pneumocystis infection of rats, relapse, and chemotherapy.

Authors:  J K Frenkel; J T Good; J A Shultz
Journal:  Lab Invest       Date:  1966-10       Impact factor: 5.662

9.  Pneumocystis carinii pneumonia. Studies on the diagnosis and treatment.

Authors:  D Rifkind; T D Faris; R B Hill
Journal:  Ann Intern Med       Date:  1966-11       Impact factor: 25.391

10.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  26 in total

Review 1.  Pneumocystis carinii, an opportunist in immunocompromised patients.

Authors:  M S Bartlett; J W Smith
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

2.  In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex.

Authors:  C M Shoen; O Choromanska; R C Reynolds; J R Piper; C A Johnson; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 3.  AIDS and the lung. 7. Treatment of lung disease in patients with the acquired immune deficiency syndrome.

Authors:  D M Mitchell; M A Johnson
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

4.  Pharmacokinetics of sulphamethoxazole in man: effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole.

Authors:  T B Vree; Y A Hekster; A M Baars; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

Review 5.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Therapy of pneumocystis carinii pneumonia after trimethoprim-sulfamethoxazole desensitization.

Authors:  G Papakonstantinou; H Füessl; A Matuschke; R Hehlmann
Journal:  Klin Wochenschr       Date:  1989-03-01

Review 7.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

8.  Trimethoprim-sulfamethoxazole desensitization in AIDS.

Authors:  G Papakonstantinou; H Füessl; R Hehlmann
Journal:  Klin Wochenschr       Date:  1988-04-15

9.  Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii.

Authors:  W T Hughes
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist.

Authors:  W T Hughes; D P Jacobus; C Canfield; J Killmar
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.